查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529757

混凝劑市場規模、佔有率、趨勢分析報告：按產品、按應用、按管理管道、按地區、細分市場預測，2024-2030

Coagulants Market Size, Share & Trends Analysis Report By Product (Systemic, Topical, Hemostatics), By Application (Surgeries, Trauma, Hemophilia, Bleeding), By Route Of Administration, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

混凝劑市場規模及趨勢

預計2023年全球混凝劑市場規模將達104.7億美元，預計2024年至2030年複合年成長率為7.2%。醫療市場的主要促進因素是出血性疾病和需要凝血因子進行治療的慢性疾病的日益流行。血友病、血管性血友病、血栓症等疾病需要使用凝血因子來有效管理和控制。這些疾病的全球發病率不斷上升正在推動對該市場的需求。

此外，技術進步和新型凝血療法的開發正在推動創新並擴大這一領域。製造商正在投資研發以推出更有效、更安全的產品，例如重組凝血因子產品和延長半衰期的產品。這些進展旨在改善出血性疾病患者的治療效果、減輕治療負擔並提高其整體生活品質。據美國疾病管制與預防美國稱，截至 2024 年 5 月，美國估計約有 33,000 名男性患有血友病。

此外，醫療技術和研究的進步促進了新型凝血製劑的開發，其功效和安全性得到提升。重組凝血因子產品和延長半衰期產品等創新配方為患者提供了更方便的治療選擇並帶來更好的結果。這些技術進步透過擴大可用治療方法的範圍和提高患者對治療方法的依從性來推動成長。 2024年4月，Avenacy在美國上市了FDA核准的醋酸去氨加壓素注射液，作為DDAVP注射液的非專利藥替代品。此藥用於治療中樞性糖尿病、 A型血友病、I型馮維勒布蘭氏症。

此外，旨在改善醫療基礎設施和促進預防性醫療保健的有利政府措施和政策正在推動該行業的發展。世界各國政府都致力於加強獲得優質衛生服務的機會，包括用於早期發現和管理凝血因子缺乏和高凝血狀態等疾病的診斷檢測設施。針對止血和血栓症形成研發活動的誘因也鼓勵產業參與者投資於最尖端科技的開發。例如，與疾病管制與預防中心合作的國家血友病計畫等舉措支持推進止血相關治療的研究工作。

監管要求在推動醫療產業發揮重要作用。隨著對病患安全和醫療品質的日益重視，包括食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 在內的多個監管機構正在針對醫療機構實施嚴格的準則。這些法規確保了產品的安全性、有效性和質量，從而推動了對這些產品的需求。例如，FDA 制定了現行的良好生產規範 (CGMP) 法規，以確保產品在受控條件下生產，以維持特性、強度、品質和純度。遵守這些法規要求製造商投資先進技術和設備，這推動了需求。

全球混凝劑市場報告細分

該報告預測了2018年至2030年全球、區域和國家層面的收益成長，並對每個子區隔的最新行業趨勢進行了分析。在這項研究中，Grand View Research, Inc. 根據產品、應用、給藥途徑和地區對全球凝血劑市場報告進行了細分。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章混凝劑市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 混凝劑市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 管道分析

第4章混凝劑市場：產品、估計與趨勢分析

  • 全球混凝劑市場：產品儀表板
  • 全球混凝劑市場：產品波動分析
  • 按產品分類的收益
  • 局部凝固劑
  • 系統性混凝劑
  • 止血劑

第5章混凝劑市場：應用、估算與趨勢分析

  • 全球混凝劑市場：應用儀表板
  • 全球混凝劑市場：應用變化分析
  • 按使用情況分類的收益
  • 外科手術
  • 外傷案例
  • 血友病
  • 出血性疾病
  • 其他

第6章 混凝劑市場：管理通路、預測及趨勢分析

  • 全球混凝劑市場：劑量通道儀表板
  • 全球混凝劑市場：管理通路變化分析
  • 按管理管道分類的收益
  • 局部給藥
  • 腸外給藥
  • 口服給藥

第7章 混凝劑市場：按產品、應用和施用途徑的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭格局

  • 公司/競爭對手分類
  • 供應商情況
    • 2023年主要企業市場佔有率分析
    • Johnson &Johnson.
    • Baxter International Inc.
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Sanofi SA
    • Bayer AG
    • Novo Nordisk A/S.
    • CSL Behring
    • Octapharma AG
    • Grifols SA
    • Amgen Inc.
    • Takeda Pharmaceutical Company Limited
Product Code: GVR-4-68040-347-9

Coagulants Market Size & Trends

The global coagulants market size was estimated at USD 10.47 billion in 2023 and is projected to grow at a CAGR of 7.2% from 2024 to 2030. The market in healthcare is primarily driven by the increasing prevalence of bleeding disorders and chronic diseases that require blood clotting factors for treatment. Conditions like hemophilia, von Willebrand disease, and thrombophilia necessitate the use of coagulants to manage and control them effectively. The rising incidence of these disorders globally is propelling the demand for this market.

Moreover, technological advancements and the development of novel coagulation therapies are driving innovation and expanding the sector. Manufacturers are investing in research and development to introduce more efficacious and safer products, including recombinant clotting factors and extended half-life products. These advancements aim to enhance patient outcomes, reduce treatment burden, and improve overall quality of life for individuals with bleeding disorders. According to Centers for Disease Control and Prevention, it's estimated that around 33,000 males in the U.S. are living with hemophilia as of May 2024.

Moreover, advancements in medical technology and research have led to development of novel coagulant products with improved efficacy and safety profiles. Innovations like recombinant clotting factors and extended half-life products offer patients more convenient treatment options and better outcomes. These technological advancements drive growth by expanding the range of available therapies and enhancing patient adherence to treatment regimens. In April 2024, Avenacy launched its FDA-approved Desmopressin Acetate Injection in the U.S., serving as a generic alternative to DDAVP Injection. This medication is aimed at treating central diabetes insipidus, hemophilia A, and Type I von Willebrand's disease.

Furthermore, favorable government initiatives and policies aimed at improving healthcare infrastructure and promoting preventive care are boosting the industry. Governments worldwide are focusing on enhancing access to quality healthcare services, including diagnostic testing facilities for early detection and management of disorders such as clotting factor deficiencies and hypercoagulable states. Incentives for research and development activities focused on hemostasis and thrombosis have also encouraged industry players to invest in developing cutting-edge technologies. For instance, initiatives like the National Hemophilia Program are done in collaboration with Centers for Disease Control and Prevention in the U.S. support research efforts to advance hemostasis-related treatments.

Regulatory requirements play a significant role in driving the healthcare industry. With the increasing emphasis on patient safety and quality care, several regulatory bodies including Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented strict guidelines in healthcare settings. These regulations ensure that the products are safe, effective, and of high quality, thereby driving demand for these products. For instance, the FDA has established the Current Good Manufacturing Practice (CGMP) regulations to ensure that they are product under controlled conditions to maintain their identity, strength, quality, and purity. Compliance with these regulations requires manufacturers to invest in advanced technologies and equipment, which in turn drives the demand.

Global Coagulants Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global coagulants market report based on product, application, route of administration, and region.

  • Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Topical Coagulants
  • Absorbable Gelatin
  • Oxidized Cellulose
  • Microfibrillar Collagen
  • Other topical coagulants
  • Systemic Coagulants
  • Vitamin K
  • Protamine
  • Desmopressin
  • Fibrinogen
  • Other systemic coagulants
  • Hemostatics
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Surgeries
  • Trauma Cases
  • Hemophilia
  • Bleeding Disorders
  • Other Applications
  • Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
  • Topical Administration
  • Parenteral Administration
  • Oral Administration
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

  • Latin America

Brazil

Argentina

  • Middle East and Africa (MEA)

South Africa

Saudi Arabia

Kuwait

UAE

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Route of Administration
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and Application outlook
    • 2.2.2. Route of Administration outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Coagulants Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements in diagnostic tools and treatment options
      • 3.2.1.2. Increasing prevalence of coagulants disorders and chronic diseases
      • 3.2.1.3. Expanding applications of coagulants testing in various medical fields including hematology, oncology, and critical care
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Regulatory Challenges
  • 3.3. Coagulants Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Coagulants Market: Product Estimates & Trend Analysis

  • 4.1. Global Coagulants Market: Product Dashboard
  • 4.2. Global Coagulants Market: Product Movement Analysis
  • 4.3. Global Coagulants Market by Product, Revenue
  • 4.4. Topical Coagulants
    • 4.4.1. Topical coagulants market estimates and forecasts 2018 to 2030, (USD Million)
    • 4.4.2. Absorbable Gelatin
      • 4.4.2.1. Absorbable gelatin market estimates and forecasts 2018 to 2030, (USD Million)
    • 4.4.3. Oxidized Cellulose
      • 4.4.3.1. Oxidized cellulose market estimates and forecasts 2018 to 2030, (USD Million)
    • 4.4.4. Microfibrillar Collagen
      • 4.4.4.1. Microfibrillar collagen market estimates and forecasts 2018 to 2030, (USD Million)
    • 4.4.5. Other topical coagulants
      • 4.4.5.1. Other topical coagulants market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.5. Systemic Coagulants
    • 4.5.1. Systemic coagulants market estimates and forecasts 2018 to 2030, (USD Million)
    • 4.5.2. Vitamin K
      • 4.5.2.1. Vitamin K market estimates and forecasts 2018 to 2030, (USD Million)
    • 4.5.3. Protamine
      • 4.5.3.1. Protamine market estimates and forecasts 2018 to 2030, (USD Million)
    • 4.5.4. Desmopressin
      • 4.5.4.1. Desmopressin market estimates and forecasts 2018 to 2030, (USD Million)
    • 4.5.5. Fibrinogen
      • 4.5.5.1. Fibrinogen market estimates and forecasts 2018 to 2030, (USD Million)
    • 4.5.6. Other systemic coagulants
      • 4.5.6.1. Other systemic coagulants market estimates and forecasts 2018 to 2030, (USD Million)
  • 4.6. Hemostatics
    • 4.6.1. Hemostatics coagulants market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 5. Coagulants Market: Application Estimates & Trend Analysis

  • 5.1. Global Coagulants Market: Application Dashboard
  • 5.2. Global Coagulants Market: Application Movement Analysis
  • 5.3. Global Coagulants Market Estimates and Forecasts, By Application, Revenue (USD Million)
  • 5.4. Surgeries
    • 5.4.1. Surgeries market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.5. Trauma Cases
    • 5.5.1. Trauma cases market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.6. Hemophilia
    • 5.6.1. Hemophilia market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.7. Bleeding Disorders
    • 5.7.1. Bleeding disorders market estimates and forecasts 2018 to 2030, (USD Million)
  • 5.8. Other Applications
    • 5.8.1. Other applications market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 6. Coagulants Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Global Coagulants Market: Route of Administration Dashboard
  • 6.2. Global Coagulants Market: Route of Administration Movement Analysis
  • 6.3. Global Coagulants Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)
  • 6.4. Topical Administration
    • 6.4.1. Topical administration market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5. Parenteral Administration
    • 6.5.1. Parenteral administration market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.6. Oral Administration
    • 6.6.1. Oral Administration market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 7. Coagulants Market: Regional Estimates & Trend Analysis by Product, Application, and Route of Administration

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Vendor Landscape
    • 8.2.1. List of key distributors and channel partners
    • 8.2.2. Key customers
    • 8.2.3. Key company market share analysis, 2023
    • 8.2.4. Johnson & Johnson.
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Baxter International Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Pfizer Inc.
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Bristol-Myers Squibb Company
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Sanofi S.A.
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Bayer AG
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Novo Nordisk A/S.
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. CSL Behring
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. Octapharma AG
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives
    • 8.2.13. Grifols S.A.
      • 8.2.13.1. Company overview
      • 8.2.13.2. Financial performance
      • 8.2.13.3. Product benchmarking
      • 8.2.13.4. Strategic initiatives
    • 8.2.14. Amgen Inc.
      • 8.2.14.1. Company overview
      • 8.2.14.2. Financial performance
      • 8.2.14.3. Product benchmarking
      • 8.2.14.4. Strategic initiatives
    • 8.2.15. Takeda Pharmaceutical Company Limited
      • 8.2.15.1. Company overview
      • 8.2.15.2. Financial performance
      • 8.2.15.3. Product benchmarking
      • 8.2.15.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America coagulants market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 U.S. coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S. coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S. coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9 Canada coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 10 Canada coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12 Mexico coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 13 Mexico coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 14 Mexico coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Europe coagulants market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 17 Europe coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 18 Europe coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Germany coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 20 Germany coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 21 Germany coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 Germany coagulants market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 23 UK coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 24 UK coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 25 UK coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 26 France coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 27 France coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 28 France coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 29 Italy coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 30 Italy coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 31 Italy coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 Spain coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 33 Spain coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 34 Spain coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 Denmark coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 36 Denmark coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 37 Denmark coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 38 Sweden coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 39 Sweden coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 40 Sweden coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41 Norway coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 42 Norway coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 43 Norway coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific coagulants market, by region, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 47 Aisa Pacific coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 China coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 49 China coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 50 China coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Japan coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 52 Japan coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 53 Japan coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 54 India coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 55 India coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 56 India coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57 South Korea coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 58 South Korea coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 59 South Korea coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 Australia coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 61 Australia coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 62 Australia coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 63 Thailand coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 64 Thailand coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 65 Thailand coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66 Latin America coagulants market, by region, 2018 - 2030 (USD Million)
  • Table 67 Latin America coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 68 Latin America coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 69 Latin America coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 Brazil coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 71 Brazil coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 72 Brazil coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 Argentina coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 74 Argentina coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 75 Argentina coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 MEA coagulants market, by region, 2018 - 2030 (USD Million)
  • Table 77 MEA coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 78 MEA coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 79 MEA coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 South Africa coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 81 South Africa coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 82 South Africa coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86 UAE coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 87 UAE coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 88 UAE coagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Kuwait coagulants market, by product, 2018 - 2030 (USD Million)
  • Table 90 Kuwait coagulants market, by application, 2018 - 2030 (USD Million)
  • Table 91 Kuwait coagulants market, by route of administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig.1 Market research process
  • Fig.2 Data triangulation techniques
  • Fig.3 Primary research pattern
  • Fig.4 Primary interviews in North America
  • Fig.5 Primary interviews in Europe
  • Fig.6 Primary interviews in APAC
  • Fig.7 Primary interviews in Latin America
  • Fig.8 Primary interviews in MEA
  • Fig.9 Market research approaches
  • Fig.10 Value-chain-based sizing & forecasting
  • Fig.11 QFD modeling for market share assessment
  • Fig.12 Market formulation & validation
  • Fig.13 Coagulants market: market outlook
  • Fig.14 Coagulants competitive insights
  • Fig.15 Parent market outlook
  • Fig.16 Related/ancillary market outlook
  • Fig.17 Coagulants market driver impact
  • Fig.18 Coagulants market restraint impact
  • Fig.19 Coagulants market: Product movement analysis
  • Fig.20 Coagulants market: Product outlook and key takeaways
  • Fig.21 Topical coagulants market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.22 Absorbable gelatin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.23 Oxidized cellulose market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.24 Microfibrillar collagen market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.25 Other topical coagulants market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.26 Systemic coagulants market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.27 Vitamin K market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.28 Protamine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.29 Desmopressin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.30 Fibrinogen market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.31 Other systemic coagulants market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.32 Hemostatics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.33 Coagulants market: Application product movement analysis
  • Fig.34 Coagulants market: Application product outlook and key takeaways
  • Fig.35 Surgeries market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.36 Trauma Cases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.37 Hemophilia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.38 Bleeding Disorders market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.39 Other Applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.40 Coagulants market: Route of administration movement analysis
  • Fig.41 Coagulants market: Route of administration outlook and key takeaways
  • Fig.42 Topical Administration market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.43 Parenteral Administration market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.44 Oral Administration market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig.45 Global Coagulants market: Regional outlook and key takeaways
  • Fig.46 Global Coagulants market share and leading players
  • Fig.47 North America, by country
  • Fig.48 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.49 U.S. key country dynamics
  • Fig.50 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.51 Canada key country dynamics
  • Fig.52 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.53 Mexico key country dynamics
  • Fig.54 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.55 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.56 UK key country dynamics
  • Fig.57 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.58 Germany key country dynamics
  • Fig.59 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.60 France key country dynamics
  • Fig.61 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.62 Italy key country dynamics
  • Fig.63 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.64 Spain key country dynamics
  • Fig.65 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.66 Denmark key country dynamics
  • Fig.67 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.68 Sweden key country dynamics
  • Fig.69 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.70 Norway key country dynamics
  • Fig.71 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.72 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.73 China key country dynamics
  • Fig.74 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.75 Japan key country dynamics
  • Fig.76 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.77 India key country dynamics
  • Fig.78 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.79 Thailand key country dynamics
  • Fig.80 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.81 South Korea key country dynamics
  • Fig.82 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.83 Australia key country dynamics
  • Fig.84 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.85 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.86 Brazil key country dynamics
  • Fig.87 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.88 Argentina key country dynamics
  • Fig.89 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.90 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.91 South Africa key country dynamics
  • Fig.92 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.93 Saudi Arabia key country dynamics
  • Fig.94 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.95 UAE key country dynamics
  • Fig.96 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.97 Kuwait key country dynamics
  • Fig.98 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig.99 Market share of key market players- coagulants market